KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim ...

Researchers discovered the crystal structure of an alternative DNA configuration within the insulin gene, providing insights ...

Molecular Cancer Research publishes articles featuring novel, basic cancer research discoveries that prioritize broad molecular and cellular processes. Areas of emphasis include cell cycle and ...

The trial evaluated monotherapy ivonescimab against monotherapy Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer ...

“Those are common molecular classifications that we now have therapies for,” Toboni said. Those drugs include Jemperli (dostarlimab-gxly), approved in August 2023 to be given in combination with ...

Summit Therapeutics’s drug ivonescimab reduced the risk of lung cancer progression or death by nearly half, compared to MSD’s blockbuster drug Keytruda (pembrolizumab) in Phase III data showcased on 8 ...

AI and biophysics are revolutionizing cancer treatment by predicting protein binding sites for personalized therapies.

Merck’s Keytruda Combo for Urothelial Carcinoma Gets EU Approval: The European Commission granted approval to Merck’s Keytruda in combination with Astellas/Pfizer’s antibody-drug conjugate ...

such as pembrolizumab (Keytruda), which are already transforming the treatment of cancer. Utilizing computational tools to engineer proteins represents the next frontier in cancer therapeutics. Our ...